← Human Trials & Peer-Reviewed Studies
Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues
Plain-language guide to PMID 9467533 (1998): placebo-controlled randomized controlled trial study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 9467533
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Van den Berghe G et al. (11 authors)
- DOI
- 10.1210/jcem.83.2.4575
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.
They had been randomly allocated to one of three combinations of peptide infusions, each administered in random order: TRH (one night) and placebo (other night), TRH + GHRP-2 (one night) and GHRP-2 (other night), or TRH + GHRH + GHRP-2 (one night) and GHRH + GHRP-2 (other night).
Blood sampling was performed every 20 min, and pituitary hormone secretion was quantified by deconvolution analysis.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intravenous infusions of TRH, GH-releasing peptide-2 (GHRP-2), and GHRH.
What Was Measured
PubMed files the paper under topics including Critical Illness, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hypothalamus, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Oligopeptides.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).
The publication is from 1998 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
TRH (Thyrotropin-Releasing Hormone): A 3-amino-acid hypothalamic hormone (protirelin) that triggers TSH and prolactin release.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
- TRH (Thyrotropin-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.